BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12483113)

  • 1. Current challenges in therapy of myelodysplastic syndromes.
    Estey EH
    Curr Opin Hematol; 2003 Jan; 10(1):60-7. PubMed ID: 12483113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndromes.
    Miller KB
    Curr Treat Options Oncol; 2000 Apr; 1(1):63-9. PubMed ID: 12057062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.
    Scott BL; Sandmaier BM; Storer B; Maris MB; Sorror ML; Maloney DG; Chauncey TR; Storb R; Deeg HJ
    Leukemia; 2006 Jan; 20(1):128-35. PubMed ID: 16270037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myelodysplastic syndromes--new treatment options].
    Germing U
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():123-6. PubMed ID: 16802536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes.
    Adès L; Itzykson R; Fenaux P
    Lancet; 2014 Jun; 383(9936):2239-52. PubMed ID: 24656536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemopoietic stem cell transplantation for myelodysplastic syndrome.
    Deeg HJ; Appelbaum FR
    Curr Opin Oncol; 2000 Mar; 12(2):116-20. PubMed ID: 10750721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes].
    Cortesão E; Tenreiro R; Ramos S; Pereira M; César P; Carda JP; Gomes M; Rito L; Magalhães E; Gonçalves AC; Silva NC; Geraldes C; Pereira A; Ribeiro L; Nascimento Costa JM; Ribeiro AB
    Acta Med Port; 2015; 28(6):720-5. PubMed ID: 26849756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patient-oriented approach to treatment of myelodysplastic syndromes.
    Cazzola M; Anderson JE; Ganser A; Hellström-Lindberg E
    Haematologica; 1998 Oct; 83(10):910-35. PubMed ID: 9830800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The myelodysplastic syndrome II. New therapeutic principles, course and prognosis].
    Hasselbalch HC; Juhl BR; Hansen PB
    Ugeskr Laeger; 2002 Jan; 164(4):479-82. PubMed ID: 11838418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and management of aplastic anemia and myelodysplastic syndrome.
    Paquette RL
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):153-61. PubMed ID: 12380966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
    Beran M
    Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The myelodysplastic syndromes: classification and prognosis.
    Komrokji R; Bennett JM
    Curr Hematol Rep; 2003 May; 2(3):179-85. PubMed ID: 12901338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
    Mishra A; Anasetti C
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.